Clinical symptoms and microbiological outcomes in tuberculosis treatment trials

Tuberculosis

Volumn 91, Issue 6, 2011, Pages 601-604

  Bark, C M ^a,b   Dietze, R ^c   Okwera, A ^d,e   Quelapio, M I ^f   Thiel, B A ^a   Johnson, J L ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^d Ugandan National Tuberculosis and Leprosy Programme   (Uganda)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f Tropical Disease Foundation Inc   (Philippines)

Author keywords

Surrogate endpoints; Symptoms; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DYSPNEA; FEVER; HEALTH STATUS; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MICROBIOLOGY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SELF REPORT; SPUTUM CULTURE; SWEAT; SYMPTOM; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 80755186918     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2011.05.007     Document Type: Article

References (12)

1. R.J. Temple A regulatory authority's opinion about surrogate endpoints W.S. Nimmo, G.T. Tucker, Clinical measurement in drug evaluation 1995 J. Wiley Chichester, West Sussex, England; New York 3 22 [Chapter 1]
2. Food and Drug Administration Public workshop. Issues in the design of clinical trials of antimycobacterial drugs for treatment of tuberculosis 2009
3. P. Hopewell, M. Cynamon, J. Starke, M. Iseman, and R. O'Brien Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration Clin Infect Dis 15 Suppl. 1 1992 S282 S295
4. C.A. Marra, F. Marra, L. Colley, S. Moadebi, R.K. Elwood, and J.M. Fitzgerald Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection Chest 133 2008 396 403 (Pubitemid 351272397)
5. M. Dhuria, N. Sharma, S. Narender Pal, J. Ram Chander, R. Saha, and I. Gopal Krishan A study of the impact of tuberculosis on the quality of life and the effect after treatment with DOTS Asia Pac J Public Health 21 2009 312 320
6. J.L. Johnson, D.J. Hadad, R. Dietze, E.L. Maciel, B. Sewali, P. Gitta, A. Okwera, R.D. Mugerwa, M.R. Alcaneses, M.I. Quelapio, T.E. Tupasi, L. Horter, S.M. Debanne, K.D. Eisenach, and W.H. Boom Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion Am J Respir Crit Care Med 180 2009 558 563
7. B.S. Strong, and G.P. Kubica Isolation and identification of Mycobacterium tuberculosis: a guide for the level II laboratory 1981 U.S. Department of Health and Human Services - Centers for Disease Control and Prevention Atlanta, Georgia
8. A. Falk, J.B. O'Connor, P.C. Pratt, W.R. Webb, J.A. Wier, and E. Wolinsky Classification of pulmonary tuberculosis Diagnostic standards and classification of tuberculosis 12th ed 1969 National Tuberculosis and Respiratory Disease Association New York 68 76
9. S. den Boon, N.W. White, S.W. van Lill, M.W. Borgdorff, S. Verver, C.J. Lombard, E.D. Bateman, E. Irusen, D.A. Enarson, and N. Beyers An evaluation of symptom and chest radiographic screening in tuberculosis prevalence surveys Int J Tuberc Lung Dis 10 2006 876 882 (Pubitemid 44197848)
10. D. Salkin Tuberculosis as a cause of upper lobe bronchiectasis Calif Med 73 1950 577 580
11. W.G. Allan, D.J. Girling, P.M. Fayers, and W. Fox The symptoms of newly diagnosed pulmonary tuberculosis and patients' attitudes to the disease and to its treatment in Hong Kong Tubercle 60 1979 211 223 (Pubitemid 10167305)
12. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 1996 605 613 (Pubitemid 126450094)